Quality of life in patients with blepharospasm;Kvaliteta života kod osoba oboljelih od blefarospazma

Collegium Antropologicum

Volumn 37, Issue 1, 2013, Pages 29-33

  Biuk, Dubravka ^a   Karin, Anita Alegić ^b   Matić, Suzana ^a   Barać, Josip ^a   Benašić, Tvrtka ^a   Stiglmayer, Neda ^c  

^a JOSIP JURAJ STROSSMAYER UNIVERSITY OF OSIJEK   (Croatia)

^b University of Zagreb School of Medicine   (Croatia)

^c KBC Zagreb   (Croatia)

Author keywords

Blepharospasm; Botulinum neurotoxin Type A; Quality of life; WHOQOL BREF

Indexed keywords

BOTULINUM TOXIN A;

AGED; ARTICLE; BLEPHAROSPASM; FEMALE; HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BLEPHAROSPASM; BOTULINUM TOXINS, TYPE A; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84875980037     PISSN: 03506134     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. WHOQOL GROUP, Int J Mental Health, 23 (1994) 24.
2. CUMMINS RA, Soc Indic Res, 35 (1995) 179. DOI: 10.1007/BF01079026.
3. CUMMINS RA, Soc Indic Res, 52 (2000) 55. DOI: 10.1023/A:1007027822 521.
4. ZELJKO-PENAVIĆ J, ŠITUM M, ŠIMIĆ D, VURNEK-ŽIVKOVIĆ M, Coll Antropol, 34 (2010) 195.
5. POLJIČANIN T, AJDUKOVIĆ D, ŠEKERIJA M, PIBERNIK-OKANOVIĆ M, METELKO Ž, VULETIĆ MAVRINAC G, BMC Public Health, 10 (2010) 12. DOI: 10.1186/1471-2458-10-12.
6. FAHN S, BRESSMAN SB, MARSDEN CD, Dystonia 3: Advances in Neurology (Lippincott-Raven, Philadelphia, 1998 121).
7. JANKOVIC J, FORD J, Ann Neurol, 13 (1988) 402.
8. GRANDANS F, ELSTON J, QUINN N, MARSDEN CD, J Neurol Neurosurg Psychiatry, 51 (1988) 767.
9. SALORIO PD, CONTE RQ, Ophthalmologic causes of blepharospasm. In: JANKOVIC J, TOLOSA E (Eds). Advances in neurology (Raven Press, New York, 1988).
10. WENZEL T, SCHNIDER P, GRIENGL H, BIRNER P, NEPP J, J Psychosom Res, 48 (2000) 589. DOI: 10.1016/S0022-3999(99) 00105-1.
11. OCHUDLO S, BRYNIARSKI P, OPALA G, Parkinsonism Relat Disord, 13 (2007) 505. DOI: 10.1016/j.parkreldis.2007.03.006.
12. SCOTT AB, KENNEDY RA, STUBBS HA, Arch Ophthalmol, 103 (1985) 347. DOI: 10.1007/s00702-010-0546-9.
13. GREEN P, FAHN S, BRIN M, BLITZER A, Botulinum toxin therapy. In: MARSDEN C, FAHN S (Eds) Movement Disorders 3 (Butterworth--Heinemann, Oxford,1984).
14. WIRTSCHAFTER JD, Ophthalmology, 98 (1991) 357. DOI: 10.1097/00004397-199103140-00011.
15. DEFAZIO G, BERARDELLI A, ABBRUZZESE G, J Neurol Neurosurg Psychiatry, 67 (1999) 613. DOI: 10. 1212/WNL.0b013e3182299e13.
16. ROVERE H, ROSSINI S, REIMAO R, Arq Neuro Psiquiatria, 66 (2008). DOI: 10.1590/S0004-282X2008000 200004.
17. TUCHA O, NAUMANN M, BERG DR, ALDERS GL, LANGE KV, Acta Neurol Scand, 103 (2001) 49. DOI: 10.1034/j.1600-0404. 2001.00109.
18. MACANDIE K, KEMP E, Orbit, 23 (2004) 4, 207. DOI: 10.1080/01676830490506041.
19. BRAJKOVIĆ L, GODAN A, GODAN LJ, Croat Med J, 50 (2009) 182. DOI: 10.3325/cmj.2009.50.182.
20. SKEVINGTON SM, LOTFY M, O'CONNELL KA, The World Health Organization's WHOQOL--BREF quality of life assessment: Psychometric properties and results of the internationl field trial, Quality of Life Research, 13 (2004) 299. DOI: 10.1023/B:QURE.0000015317.71791.be.
21. RAPLEY M, Quality of Life Research. A critical introduction. SAGE Publications. London Thousand Oaks New-Delhi, 2003.
22. WHOQOL GROUP, Psychol Med 28 (1998) 551.
23. HARRISON AR, ERICKSON JP, ANDERSON JS, LEE MS, Ophthal Plast Reconstr Surg, 24 (2008) 113. DOI: 10.1097/IOP.0b013 e31816386e1.